BR112012029897A2 - método para reduzir a quantidade de uma serina protease ou um zimogênio de serina protease em uma composição, método para preparar uma composição, composição de proteína derivada de plasma, e, método para tratamento de uma doença - Google Patents
método para reduzir a quantidade de uma serina protease ou um zimogênio de serina protease em uma composição, método para preparar uma composição, composição de proteína derivada de plasma, e, método para tratamento de uma doençaInfo
- Publication number
- BR112012029897A2 BR112012029897A2 BR112012029897A BR112012029897A BR112012029897A2 BR 112012029897 A2 BR112012029897 A2 BR 112012029897A2 BR 112012029897 A BR112012029897 A BR 112012029897A BR 112012029897 A BR112012029897 A BR 112012029897A BR 112012029897 A2 BR112012029897 A2 BR 112012029897A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- serine protease
- disease
- treating
- preparing
- Prior art date
Links
- 102000012479 Serine Proteases Human genes 0.000 title 2
- 108010022999 Serine Proteases Proteins 0.000 title 2
- 102000010911 Enzyme Precursors Human genes 0.000 title 1
- 108010062466 Enzyme Precursors Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
- A61K39/39525—Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/12—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the preparation of the feed
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
- B01D15/424—Elution mode
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
- B01J20/10—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Marine Sciences & Fisheries (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2010202125A AU2010202125B1 (en) | 2010-05-26 | 2010-05-26 | A method to produce an immunoglobulin preparation with improved yield |
US12/789,365 US8993734B2 (en) | 2010-05-26 | 2010-05-27 | Method to produce an immunoglobulin preparation with improved yield |
US12/842,944 US8304524B2 (en) | 2009-07-23 | 2010-07-23 | Manufacture of factor H (FH) and FH-derivatives from plasma |
PCT/US2011/038247 WO2011150284A2 (en) | 2010-05-26 | 2011-05-26 | Removal of serine proteases by treatment with finely divided silicon dioxide |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012029897A2 true BR112012029897A2 (pt) | 2016-08-16 |
Family
ID=42727304
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012029893-3A BR112012029893B1 (pt) | 2010-05-26 | 2010-05-27 | Método para preparar uma composição de igg enriquecida a partir de plasma |
BR112012029897A BR112012029897A2 (pt) | 2010-05-26 | 2011-05-26 | método para reduzir a quantidade de uma serina protease ou um zimogênio de serina protease em uma composição, método para preparar uma composição, composição de proteína derivada de plasma, e, método para tratamento de uma doença |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012029893-3A BR112012029893B1 (pt) | 2010-05-26 | 2010-05-27 | Método para preparar uma composição de igg enriquecida a partir de plasma |
Country Status (25)
Country | Link |
---|---|
US (6) | US8993734B2 (pt) |
EP (6) | EP2445482B1 (pt) |
JP (6) | JP5876474B2 (pt) |
KR (3) | KR101647617B1 (pt) |
CN (5) | CN102970975B (pt) |
AR (4) | AR076800A1 (pt) |
AU (8) | AU2010202125B1 (pt) |
BR (2) | BR112012029893B1 (pt) |
CA (2) | CA2800155A1 (pt) |
CL (3) | CL2012003290A1 (pt) |
CO (2) | CO6660439A2 (pt) |
DK (3) | DK2554160T3 (pt) |
EA (4) | EA023446B1 (pt) |
ES (4) | ES2536093T3 (pt) |
HK (6) | HK1170168A1 (pt) |
HR (3) | HRP20140944T1 (pt) |
HU (1) | HUE064400T2 (pt) |
IL (2) | IL223149A (pt) |
MX (4) | MX364252B (pt) |
MY (3) | MY160551A (pt) |
PL (4) | PL2554160T3 (pt) |
PT (3) | PT2554160E (pt) |
SG (3) | SG185724A1 (pt) |
TW (3) | TWI531577B (pt) |
WO (1) | WO2011149472A1 (pt) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI532498B (zh) | 2008-03-17 | 2016-05-11 | 巴克斯特保健公司 | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
DK2477603T3 (en) * | 2009-09-17 | 2016-06-13 | Baxalta Inc | STABLE CO-DEVELOPMENT OF hyaluronidase and Immunoglobulin, AND METHODS OF USE THEREOF |
US10787701B2 (en) | 2010-04-05 | 2020-09-29 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
AU2010202125B1 (en) | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
WO2011150284A2 (en) | 2010-05-26 | 2011-12-01 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
JP5830096B2 (ja) * | 2010-07-23 | 2015-12-09 | バクスター、インターナショナル、インコーポレイテッド | 血漿由来インターα阻害タンパク質(IaIp)の製造方法 |
WO2012136172A1 (es) * | 2011-04-08 | 2012-10-11 | Universidad De Costa Rica | Método para la producción de formulaciones inyectables de productos proteicos hemoderivados y productos obtenidos utilizando dicho metodo |
PL2791675T3 (pl) | 2011-12-13 | 2018-10-31 | Baxalta GmbH | Pomiar autoprzeciwciał w warunkach niskiej przewodności |
TWI629283B (zh) | 2012-02-23 | 2018-07-11 | 巴克斯歐塔公司 | 來自血漿中的免疫球蛋白之i-iv-1部分沉澱 |
RU2487725C1 (ru) * | 2012-03-15 | 2013-07-20 | Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации (ФГУП "НПО "Микроген" Минздрава России) | Способ получения концентрированного иммуноглобулинового препарата для подкожного введения |
CN103197053B (zh) * | 2013-03-15 | 2015-02-18 | 上海市血液中心 | 一种抗IgA抗体检测试剂盒 |
AU2013203043B2 (en) | 2013-03-15 | 2016-10-06 | Takeda Pharmaceutical Company Limited | Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs |
CN104086646B (zh) * | 2014-07-03 | 2018-10-09 | 成都蓉生药业有限责任公司 | 血液制品中fv沉淀的制备方法 |
CN104086642A (zh) * | 2014-07-03 | 2014-10-08 | 成都蓉生药业有限责任公司 | 血液制品中fi+iii上清的制备方法 |
CN104072601A (zh) * | 2014-07-03 | 2014-10-01 | 成都蓉生药业有限责任公司 | 血液制品中fii沉淀的制备方法 |
GB201413227D0 (en) * | 2014-07-25 | 2014-09-10 | Bioproducts Lab Ltd | Process |
WO2016064955A1 (en) | 2014-10-21 | 2016-04-28 | The General Hospital Corporation | Methods of diagnosis and treatment of tuberculosis and infection |
CN204424090U (zh) | 2014-11-28 | 2015-06-24 | 比亚迪股份有限公司 | 薄膜电容器 |
US20160289300A1 (en) * | 2015-04-02 | 2016-10-06 | Kieu Hoang | Method of manufacturing intravenous immunoglobulin from fraction iii |
WO2016161422A1 (en) * | 2015-04-02 | 2016-10-06 | Kieu Hoang | A method of manufacturing and purifiying prothrombin complex concentrate from fraction iii for intraveneous injection and a method of curing and preventing hemophilia a with inhibitors or hempophilia b patients infected with hiv-1 and hiv-2 |
WO2016161423A1 (en) * | 2015-04-02 | 2016-10-06 | Kieu Hoang | Process of cloning and further purification to make a recombinant intravenous immunoglobulin |
WO2017058879A1 (en) * | 2015-09-29 | 2017-04-06 | Kieu Hoang | A method of manufacturing intravenous immunoglobulin from fraction iii |
WO2017062536A2 (en) * | 2015-10-06 | 2017-04-13 | Kieu Hoang | A method of manfacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv |
CN106800583A (zh) * | 2015-11-26 | 2017-06-06 | 上海洲跃生物科技有限公司 | 一种速溶无析出的冻干人纤维蛋白原制备工艺 |
EP3275897A1 (en) * | 2016-07-27 | 2018-01-31 | Biotest AG | Process for preparing immunoglobulin compositions |
WO2018050873A1 (en) | 2016-09-16 | 2018-03-22 | Leukocare Ag | A novel method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation |
US20190216925A1 (en) * | 2016-09-16 | 2019-07-18 | Leukocare Ag | A Novel Method for Stabilization of a Biopharmaceutical Drug Product During Processing |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
CN110831627A (zh) * | 2017-04-21 | 2020-02-21 | 瑞士杰特贝林生物制品有限公司 | 用于治疗慢性炎症性脱髓鞘性多发性神经病的免疫球蛋白产品 |
WO2019121846A1 (en) * | 2017-12-19 | 2019-06-27 | CSL Behring Lengnau AG | Protein purification and virus inactivation with alkyl glycosides |
KR20210005053A (ko) * | 2018-04-12 | 2021-01-13 | 암젠 인크 | 안정한 단백질 조성물의 제조 방법 |
CN108733099B (zh) * | 2018-05-31 | 2020-08-11 | 上海药明生物技术有限公司 | 低pH孵育和中和的自动调节系统及方法 |
JP2022551566A (ja) * | 2019-10-11 | 2022-12-12 | 武田薬品工業株式会社 | 第XIa因子のヘパリン非感受性アッセイ |
EP4054597A4 (en) | 2019-11-04 | 2024-02-21 | Alkahest, Inc. | BLOOD PLASMA FRACTIONS FOR USE IN MUSCLE REGENERATION |
CA3179750A1 (en) | 2020-04-10 | 2022-04-07 | Plasma Technologies, Llc | Compositions and methods for simplified high efficiency isolation of proteins |
CN111961130B (zh) * | 2020-08-31 | 2021-09-10 | 华兰生物工程重庆有限公司 | 一种从血浆中提取并分离IgM和IgG的方法 |
WO2022069945A1 (en) * | 2020-10-01 | 2022-04-07 | Takeda Pharmaceutical Company Limited | Plasma fractionation process utilizing spray-dried human plasma |
KR20230125282A (ko) | 2020-12-28 | 2023-08-29 | 플라즈마 테크놀로지스, 엘엘씨 | 면역글로불린 G의 공정 규모 단리를 위한 시스템 및방법 (Systems and Methods for Process Scale Isolation of Immunoglobulin G) |
CN112574296B (zh) * | 2020-12-30 | 2023-05-19 | 中国医学科学院输血研究所 | 一种模拟IVIg的多人份混合人血浆IgG样品的分离纯化方法 |
MX2024001187A (es) | 2021-07-29 | 2024-02-27 | Csl Behring Ag | Metodo para purificar inmunoglobulina g y usos de la misma. |
CA3236213A1 (en) | 2021-10-27 | 2023-05-04 | Eugene ZURLO | Compositions and methods for isolating proteins |
KR20230121373A (ko) * | 2022-02-11 | 2023-08-18 | 주식회사 녹십자 | 인자 xiii의 정제방법 |
AU2023230335A1 (en) | 2022-03-07 | 2024-08-29 | Takeda Pharmaceutical Company Limited | Affinity chromatographic production of clinical human igg products |
AU2023232562A1 (en) | 2022-03-08 | 2024-09-05 | Equashield Medical Ltd | Fluid transfer station in a robotic pharmaceutical preparation system |
WO2023215722A1 (en) | 2022-05-02 | 2023-11-09 | Takeda Pharmaceutical Company Limited | Methods of preparing cohn pool concentrate from blood plasma through ultrafiltration |
AR129690A1 (es) | 2022-06-22 | 2024-09-18 | Ageronix SA | a1-ANTITRIPSINA PARA SU USO EN EL TRATAMIENTO DE ENFERMEDADES O TRASTORNOS DEL SISTEMA NERVIOSO COMO LA POLINEUROPATÍA DESMIELINIZANTE INFLAMATORIA CRÓNICA Y UN KIT |
WO2024200757A1 (en) | 2023-03-29 | 2024-10-03 | Csl Behring Ag | Methods of identifying immunoglobulin associated with adverse reactions |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2390074A (en) * | 1942-02-09 | 1945-12-04 | Research Corp | Protein product and process |
SE348942B (pt) | 1970-06-02 | 1972-09-18 | Statens Bakteriologiska Labor | |
US4056614A (en) | 1972-09-22 | 1977-11-01 | Marc Bonneau | Immunity depressant medicine |
US3998946A (en) * | 1975-04-23 | 1976-12-21 | The Regents Of The University Of Minnesota | Fibrinogen-free plasminogen-plasmin-free plasma and method of preparing and using same |
DE2801123C2 (de) * | 1977-01-26 | 1986-01-02 | Armour Pharma GmbH & Co KG, 3440 Eschwege | Verfahren zur Herstellung eines intravenös applizierbaren Serumeiweiß-Präparates |
US4136094A (en) | 1977-08-31 | 1979-01-23 | The Regents Of The University Of Minnesota | Preparation of intravenous human and animal gamma globulins and isolation of albumin |
US4296027A (en) * | 1977-08-31 | 1981-10-20 | The Regents Of The University Of Minnesota | Pure intravenous human and animal gamma globulins |
US4550019A (en) * | 1978-03-22 | 1985-10-29 | South Africa Inventions Development Corporation | Manufacture and use of fowl egg antibodies |
US4357272A (en) * | 1978-03-22 | 1982-11-02 | The South African Inventions Development Corporation | Recovering purified antibodies from egg yolk |
DE2901822A1 (de) * | 1979-01-18 | 1980-07-31 | Biotest Serum Institut Gmbh | Verfahren zur herstellung einer fuer die intravenoese applikation geeigneten immunglobulinloesung, die igm in ankonzentrierter form enthaelt |
DE2902158A1 (de) | 1979-01-20 | 1980-07-31 | Biotest Serum Institut Gmbh | Verfahren zur herstellung von fibrinogen, einem die gerinnungsfaktoren ii, vii, ix und x enthaltenden prothrombinkomplex, antithrombin iii und einer loesung von lagerstabilen serumproteinen |
US4228154A (en) | 1979-02-26 | 1980-10-14 | Armour Pharmaceutical Company | Purification of plasma albumin by ion exchange chromatography |
US4378346A (en) * | 1979-08-15 | 1983-03-29 | Tankersley Donald L | Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production |
US4499073A (en) * | 1981-08-24 | 1985-02-12 | Cutter Laboratories, Inc. | Intravenously injectable immune serum globulin |
JPS5855432A (ja) | 1981-09-29 | 1983-04-01 | Fujirebio Inc | 静脈注射用免疫グロブリンの製法 |
US4439358A (en) | 1982-06-17 | 1984-03-27 | Miles Laboratories, Inc. | Method of preparing alpha-1-proteinase inhibitor |
US4624780A (en) | 1982-06-28 | 1986-11-25 | Alpha Therapeutic Corporation | Fractionation of blood plasma |
DE3247150A1 (de) | 1982-12-21 | 1984-06-28 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Gerinnungsaktive plasmaproteinloesung, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von stoerungen des haemostasesystems |
DK166763C (da) | 1983-03-16 | 1993-07-12 | Immuno Ag | Immunoglobulin-g-holdig fraktion |
US5061237A (en) | 1985-07-02 | 1991-10-29 | Cytomed Medizintechnik Gmbh | Method of purifying whole blood |
DE3523615A1 (de) | 1985-07-02 | 1987-01-15 | Cytomed Medizintechnik | Medizinisches geraet, insbesondere kanuele, katheter oder implantat |
JPH0742235B2 (ja) | 1985-11-08 | 1995-05-10 | 三共株式会社 | 自己免疫性疾病の予防・治療剤 |
US5136094A (en) | 1988-03-10 | 1992-08-04 | Air Products And Chemicals, Inc. | Process for the synthesis of secondary formamides |
US5055447A (en) | 1988-07-28 | 1991-10-08 | Genentech, Inc. | Method and compositions for the treatment and prevention of septic shock |
JP2871709B2 (ja) | 1988-11-21 | 1999-03-17 | 住友製薬株式会社 | 免疫グロブリンg結合活性を有する新規な蛋白質プロテインh、該蛋白質をコードする遺伝子及び該蛋白質の製造法 |
US5177194A (en) | 1990-02-01 | 1993-01-05 | Baxter International, Inc. | Process for purifying immune serum globulins |
EP0440509A3 (en) * | 1990-02-02 | 1991-12-18 | Common Services Agency | Novel cell growth medium components and process for producing same |
ES2074490T5 (es) * | 1990-03-22 | 2004-02-16 | Biotest Pharma Gmbh | Procedimiento para la elaboracion de un preparado de inmunoglobulina g tolerable por via intravenosa. |
US5130451A (en) * | 1991-03-28 | 1992-07-14 | Amoco Corporation | Process for preparing carboxyaryl phosphates |
US5324425A (en) * | 1992-08-26 | 1994-06-28 | Ellison Billy L | Method and apparatus for removing solids from aqueous wash solutions |
FR2706466B1 (fr) | 1993-06-14 | 1995-08-25 | Aetsrn | Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré. |
FR2711371B1 (fr) | 1993-10-18 | 1995-12-29 | Aetsrn | Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu. |
US5610285A (en) | 1994-08-24 | 1997-03-11 | Bayer Corporation | Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions |
DE4435485C1 (de) | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
AUPN858596A0 (en) * | 1996-03-08 | 1996-04-04 | Csl Limited | Filtration of plasma precipitates using cellulose filter aid |
TW491855B (en) | 1996-08-07 | 2002-06-21 | Csl Ltd | Purification of immunoglobulins |
US5783640A (en) * | 1997-03-04 | 1998-07-21 | The Goodyear Tire & Rubber Company | Rubber compositions containing a disodium salt of 2, 2'-dithiosalicyclic acid |
TW541179B (en) | 1997-03-19 | 2003-07-11 | Green Cross Corp | Process for preparing immunoglobulin preparation |
GB9705810D0 (en) | 1997-03-20 | 1997-05-07 | Common Services Agency | Intravenous immune globulin |
AT407114B (de) | 1997-06-10 | 2000-12-27 | Immuno Ag | Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung |
US5886154A (en) | 1997-06-20 | 1999-03-23 | Lebing; Wytold R. | Chromatographic method for high yield purification and viral inactivation of antibodies |
PT911037E (pt) | 1997-10-23 | 2002-12-31 | Mitsubishi Pharma Corp | Preparacao de imunoglobulina armazenavel a temperatura ambiente para injeccao intravenosa |
US20020114802A1 (en) | 1998-02-10 | 2002-08-22 | Tjellstrom Bo Arthur Einar | Oral immunoglobulin treatment for inflammatory bowel disease |
AT406873B (de) | 1998-02-25 | 2000-10-25 | Immuno Ag | Verfahren zur abreicherung von pathogenen aus proteinhaltigen lösungen |
DE19932782A1 (de) * | 1999-07-14 | 2001-01-18 | Biotest Pharma Gmbh | Verfahren zur chromatographischen Fraktionierung von Plasma oder Serum, so erhaltene Präparate und deren Verwendung |
ATE290837T1 (de) | 1999-10-21 | 2005-04-15 | Alcon Inc | Medikamentenversorgung der sub-tenon |
DE10008519C1 (de) | 2000-02-21 | 2001-07-12 | Dica Technologies Ag | Verfahren und Kommunikationseinrichtungen zum Aufbau von gesicherten E-Mail-Verkehr zwischen Mail-Domains des Internet |
DE10008619A1 (de) * | 2000-02-24 | 2001-09-06 | Immuno Vet As Lynge | Mikroorganismenfreies IgG-Präparat, Verfahren zu seiner Herstellung und seine Verwendung in der Tieraufzucht und in der Tiermast |
SE0001128D0 (sv) | 2000-03-30 | 2000-03-30 | Amersham Pharm Biotech Ab | A method of producing IgG |
US20020098182A1 (en) | 2000-09-28 | 2002-07-25 | Richard Weisbart | Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin G |
EP1326893A2 (de) | 2000-10-13 | 2003-07-16 | Octapharma AG | Bikunin enthaltende plasmafraktion, verfahren zu ihrer herstellung und ihrer verwendung |
FR2824568B1 (fr) | 2001-05-11 | 2004-04-09 | Lab Francais Du Fractionnement | Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique |
WO2003028668A2 (en) | 2001-10-04 | 2003-04-10 | Protein Therapeutics, Inc. | Gammaglobulin treatment of immune disorders |
US6893639B2 (en) | 2001-10-19 | 2005-05-17 | Hemacare Corporation | Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates |
US7777006B2 (en) * | 2002-12-31 | 2010-08-17 | Csl Behring L.L.C. | Method for purification of alpha-1-antitrypsin |
DE602004025100D1 (de) * | 2003-05-23 | 2010-03-04 | Novo Nordisk Healthcare Ag | Stabilisierung von proteinen in lösung |
WO2005012354A1 (en) | 2003-07-31 | 2005-02-10 | Zlb Behring Gmbh | Method for extending the half-life of fviii |
US20050054003A1 (en) | 2003-09-10 | 2005-03-10 | Stenland Christopher J. | Prion clearance using particulate metal oxides |
EP3087991A1 (en) | 2003-11-08 | 2016-11-02 | Prothera Biologics | Composition of inter-alpha inhibitor proteins from human plasma for therapeutic use |
MXPA06008435A (es) | 2004-01-30 | 2007-05-23 | Suomen Punainen Risti Veripalvelu | Proceso de manufactura de una inmunoglobulina libre de virus. |
ES2407380T5 (es) | 2004-02-27 | 2017-07-07 | Octapharma Ag | Procedimiento para proporcionar una preparación de anticuerpos purificada, sin riesgo respecto a virus |
EP2302076B1 (en) | 2005-02-14 | 2014-11-12 | University of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
US8715649B2 (en) | 2005-06-07 | 2014-05-06 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity |
US20080261869A1 (en) * | 2007-04-20 | 2008-10-23 | Leland Shapiro | Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity |
US7807435B2 (en) | 2005-08-11 | 2010-10-05 | Baxter International Inc. | Method for the purification of alpha-1 proteinase inhibitor (a1PI) |
WO2007038995A1 (en) | 2005-09-19 | 2007-04-12 | Csl Behring Gmbh | Factor h for the treatment of chronic nephropathies and production thereof |
FR2894145B1 (fr) | 2005-12-07 | 2008-10-17 | Lab Francais Du Fractionnement | Utilisation de facteur h du complement a titre de medicament |
JP2009524622A (ja) * | 2006-01-25 | 2009-07-02 | オクタファルマ アクチェン ゲゼルシャフト | 創傷治癒支援因子の精製および使用 |
US8476234B2 (en) | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
EP1852443A1 (en) * | 2006-05-05 | 2007-11-07 | Leukocare AG | Biocompatible three dimensional matrix for the immobilization of biological substances |
DE102007001521A1 (de) * | 2007-01-10 | 2008-07-17 | Matthias, Torsten, Dr. | Verwendung von Cohn-Oncley-Fraktionen II und II/III zur Behandlung des systemischen Lupus erythematodes |
WO2008113589A1 (en) | 2007-03-20 | 2008-09-25 | Csl Behring Gmbh | Methods for industrial scale production of therapeutic complement factor h preparations from human plasma |
DE202007004346U1 (de) | 2007-03-21 | 2007-10-31 | Rehau Ag + Co | Rohranordnung |
DK2167117T3 (da) | 2007-06-13 | 2012-11-19 | Csl Behring Gmbh | Anvendelse af VWF-stabiliserede FVIII-præparater til ekstravaskulær administration til terapeutisk og profylaktisk behandling af blødningsforstyrrelser |
ES2477293T3 (es) | 2007-08-13 | 2014-07-16 | Baxter International Inc. | Modulación por IVIG de quimioquinas para el tratamiento de la esclerosis múltiple, la enfermedad de Alzheimer y la enfermedad de Parkinson |
EP2195025B1 (en) * | 2007-10-02 | 2013-11-06 | CSL Limited | Therapeutic antibody purification method and method of use |
TWI515006B (zh) | 2007-12-28 | 2016-01-01 | 巴克斯特國際公司 | 重組vwf調配物 |
CN101249265B (zh) * | 2008-04-11 | 2010-10-27 | 三九集团湛江开发区双林药业有限公司 | 静脉注射用人乙肝免疫球蛋白及其制备方法 |
BRPI0913949A2 (pt) | 2008-05-28 | 2015-10-20 | Pro Thera Biolog Llc | preparação e composição de proteínas inibidoras inter-alfa a partir de sangue |
JP5832285B2 (ja) | 2008-06-24 | 2015-12-16 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 延長されたインビボ半減期を有する第viii因子、フォン・ヴィレブランド因子又はそれらの複合体 |
CN201169579Y (zh) * | 2008-06-30 | 2008-12-24 | 山东泰邦生物制品有限公司 | 一种人血白蛋白分离用乙醇雾化扩散装置 |
TWI508735B (zh) | 2008-10-21 | 2015-11-21 | 巴克斯特國際公司 | 凍乾的重組vwf調配物 |
WO2010056909A1 (en) | 2008-11-12 | 2010-05-20 | Baxter International Inc. | Purification of butyrylcholinesterase using membrane adsorption |
MY157239A (en) | 2009-05-27 | 2016-05-13 | Baxalta Inc | A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use |
US8304524B2 (en) | 2009-07-23 | 2012-11-06 | Baxter International Inc. | Manufacture of factor H (FH) and FH-derivatives from plasma |
WO2011150284A2 (en) | 2010-05-26 | 2011-12-01 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
AU2010202125B1 (en) | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
AU2011274467B2 (en) | 2010-07-08 | 2015-01-15 | Takeda Pharmaceutical Company Limited | Method of producing recombinant high molecular weight vWF in cell culture |
JP5830096B2 (ja) | 2010-07-23 | 2015-12-09 | バクスター、インターナショナル、インコーポレイテッド | 血漿由来インターα阻害タンパク質(IaIp)の製造方法 |
-
2010
- 2010-05-26 AU AU2010202125A patent/AU2010202125B1/en active Active
- 2010-05-27 ES ES12190138.3T patent/ES2536093T3/es active Active
- 2010-05-27 PT PT121901383T patent/PT2554160E/pt unknown
- 2010-05-27 PL PL12190138T patent/PL2554160T3/pl unknown
- 2010-05-27 SG SG2012086245A patent/SG185724A1/en unknown
- 2010-05-27 TW TW099117123A patent/TWI531577B/zh active
- 2010-05-27 EP EP10727539.8A patent/EP2445482B1/en active Active
- 2010-05-27 PL PL10727539T patent/PL2445482T3/pl unknown
- 2010-05-27 MX MX2014006981A patent/MX364252B/es unknown
- 2010-05-27 CA CA2800155A patent/CA2800155A1/en not_active Abandoned
- 2010-05-27 EA EA201291355A patent/EA023446B1/ru not_active IP Right Cessation
- 2010-05-27 AR ARP100101844A patent/AR076800A1/es active IP Right Grant
- 2010-05-27 JP JP2013512585A patent/JP5876474B2/ja active Active
- 2010-05-27 ES ES14176511T patent/ES2959234T3/es active Active
- 2010-05-27 EA EA201500848A patent/EA034602B1/ru not_active IP Right Cessation
- 2010-05-27 ES ES10727539.8T patent/ES2525492T3/es active Active
- 2010-05-27 BR BR112012029893-3A patent/BR112012029893B1/pt active IP Right Grant
- 2010-05-27 CN CN201080067929.6A patent/CN102970975B/zh active Active
- 2010-05-27 HU HUE14176511A patent/HUE064400T2/hu unknown
- 2010-05-27 WO PCT/US2010/036470 patent/WO2011149472A1/en active Application Filing
- 2010-05-27 MY MYPI2012005077A patent/MY160551A/en unknown
- 2010-05-27 PL PL14176511.5T patent/PL2803349T3/pl unknown
- 2010-05-27 US US12/789,365 patent/US8993734B2/en active Active
- 2010-05-27 EP EP12190138.3A patent/EP2554160B1/en active Active
- 2010-05-27 SG SG10201505161SA patent/SG10201505161SA/en unknown
- 2010-05-27 MX MX2012013682A patent/MX349815B/es active IP Right Grant
- 2010-05-27 CN CN201510158213.1A patent/CN104958761B/zh active Active
- 2010-05-27 DK DK12190138T patent/DK2554160T3/da active
- 2010-05-27 PT PT107275398T patent/PT2445482E/pt unknown
- 2010-05-27 MY MYPI2015002952A patent/MY173299A/en unknown
- 2010-05-27 KR KR1020167002347A patent/KR101647617B1/ko active IP Right Grant
- 2010-05-27 KR KR1020127033758A patent/KR101593265B1/ko active IP Right Grant
- 2010-05-27 EP EP14176511.5A patent/EP2803349B1/en active Active
- 2010-05-27 DK DK10727539.8T patent/DK2445482T3/da active
- 2010-09-29 AU AU2010224461A patent/AU2010224461B2/en active Active
-
2011
- 2011-05-26 EA EA201291367A patent/EA025826B1/ru not_active IP Right Cessation
- 2011-05-26 ES ES11729200.3T patent/ES2505465T3/es active Active
- 2011-05-26 TW TW104127086A patent/TWI543989B/zh active
- 2011-05-26 BR BR112012029897A patent/BR112012029897A2/pt not_active Application Discontinuation
- 2011-05-26 CN CN201810967589.0A patent/CN109180776B/zh active Active
- 2011-05-26 CN CN201180036374.3A patent/CN103068365B/zh active Active
- 2011-05-26 MY MYPI2012005078A patent/MY161617A/en unknown
- 2011-05-26 SG SG2012086252A patent/SG185725A1/en unknown
- 2011-05-26 EA EA201691558A patent/EA034530B1/ru not_active IP Right Cessation
- 2011-05-26 DK DK11729200.3T patent/DK2575762T3/da active
- 2011-05-26 MX MX2012013689A patent/MX337028B/es active IP Right Grant
- 2011-05-26 EP EP20140166189 patent/EP2796128A1/en active Pending
- 2011-05-26 CN CN201510171065.7A patent/CN104840946A/zh active Pending
- 2011-05-26 CA CA2800272A patent/CA2800272A1/en not_active Abandoned
- 2011-05-26 KR KR1020127033759A patent/KR101716534B1/ko active IP Right Grant
- 2011-05-26 JP JP2013512262A patent/JP5866345B2/ja active Active
- 2011-05-26 EP EP22164436.2A patent/EP4039249A1/en active Pending
- 2011-05-26 PL PL11729200T patent/PL2575762T3/pl unknown
- 2011-05-26 EP EP11729200.3A patent/EP2575762B1/en not_active Revoked
- 2011-05-26 AU AU2011258111A patent/AU2011258111B2/en active Active
- 2011-05-26 PT PT117292003T patent/PT2575762E/pt unknown
- 2011-05-26 AR ARP110101811A patent/AR082093A1/es active IP Right Grant
- 2011-05-26 TW TW100118581A patent/TWI504607B/zh active
-
2012
- 2012-10-16 US US13/653,332 patent/US8940877B2/en active Active
- 2012-10-31 HK HK12110936.2A patent/HK1170168A1/xx unknown
- 2012-11-20 IL IL223149A patent/IL223149A/en active IP Right Grant
- 2012-11-20 IL IL223150A patent/IL223150A0/en unknown
- 2012-11-23 CL CL2012003290A patent/CL2012003290A1/es unknown
- 2012-11-23 CL CL2012003291A patent/CL2012003291A1/es unknown
- 2012-11-23 CO CO12212759A patent/CO6660439A2/es unknown
- 2012-11-23 CO CO12212751A patent/CO6660438A2/es unknown
- 2012-11-26 MX MX2019004482A patent/MX2019004482A/es unknown
-
2013
- 2013-08-06 HK HK13109199.5A patent/HK1181682A1/xx unknown
- 2013-09-25 HK HK13110932.5A patent/HK1183449A1/xx unknown
-
2014
- 2014-06-19 US US14/309,668 patent/US20150133644A1/en not_active Abandoned
- 2014-09-30 HR HRP20140944AT patent/HRP20140944T1/hr unknown
- 2014-11-14 HR HRP20141109AT patent/HRP20141109T1/hr unknown
- 2014-12-17 CL CL2014003430A patent/CL2014003430A1/es unknown
-
2015
- 2015-05-04 HR HRP20150484TT patent/HRP20150484T1/hr unknown
- 2015-05-15 HK HK15104607.0A patent/HK1203838A1/xx unknown
- 2015-08-14 JP JP2015160018A patent/JP2016053016A/ja active Pending
-
2016
- 2016-01-04 JP JP2016000025A patent/JP2016155798A/ja active Pending
- 2016-02-18 HK HK16101817.1A patent/HK1213790A1/zh unknown
- 2016-04-06 HK HK16103905.0A patent/HK1215931A1/zh unknown
- 2016-05-09 AU AU2016202973A patent/AU2016202973B2/en active Active
- 2016-10-27 JP JP2016210160A patent/JP6363676B2/ja active Active
-
2017
- 2017-11-08 US US15/807,512 patent/US11136350B2/en active Active
-
2018
- 2018-02-01 JP JP2018016073A patent/JP6592120B2/ja active Active
- 2018-02-26 AU AU2018201371A patent/AU2018201371B2/en active Active
-
2019
- 2019-01-23 AR ARP190100147A patent/AR114228A2/es unknown
-
2020
- 2020-01-19 AU AU2020200373A patent/AU2020200373B2/en active Active
-
2021
- 2021-04-16 AR ARP210101010A patent/AR121861A2/es unknown
- 2021-09-13 US US17/473,910 patent/US20210403504A1/en active Pending
- 2021-12-16 AU AU2021286395A patent/AU2021286395B2/en active Active
-
2023
- 2023-12-19 US US18/545,528 patent/US20240117009A1/en active Pending
-
2024
- 2024-07-11 AU AU2024204779A patent/AU2024204779A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012029897A2 (pt) | método para reduzir a quantidade de uma serina protease ou um zimogênio de serina protease em uma composição, método para preparar uma composição, composição de proteína derivada de plasma, e, método para tratamento de uma doença | |
IL244154A0 (en) | Botulinum neurotoxin for use in the treatment of depression | |
BR112014002614A2 (pt) | anticorpo ou um fragmento do mesmo, que tem reatividade imunológica com uma proteína caprin-1, composição farmacêutica e combinação farmacêutica para tratamento e/ou prevenção de câncer, dna e método para tratamento e/ou prevenção de câncer | |
BR112014004181A2 (pt) | composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia | |
PL2672966T3 (pl) | Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania | |
BR112013032229A2 (pt) | método de tratamento hidrocatalítico hidrotérmico de biomassa, e, composição | |
BR112014002621A2 (pt) | anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento | |
GB2508773B (en) | Large-span and special-shaped arch bridge and method for the construction thereof | |
PT2729151T (pt) | Composição farmacêutica, métodos de tratamento e suas utilizações | |
ZA201307499B (en) | Compositions and methods comprising serine protease variants | |
BR112012002137A2 (pt) | método para um polipeptídeo e/ou vírus de interesse em uma cultura de célula contínua,e, composição | |
EA201200118A1 (ru) | Дифференцировка мезенхемальных стволовых клеток | |
FI20116074A (fi) | Nestemäinen entsyymivalmiste ja menetelmä sen valmistamiseksi | |
EP2712291A4 (en) | N1 AND N2 CARBAMOYL-1,2,3-TRIAZOL SERINE HYDROLASE INHIBITORS AND METHOD THEREFOR | |
MX359181B (es) | Hidrolizado de colágeno y uso del mismo. | |
BRPI1015311A2 (pt) | método, dispositivo e kit para determinar a quantidade de polipetídeo de neurotoxina processada e processada ativa em uma solução contendo polipeptídeo de neurotoxina processada e parcialmente processada e/ou não processada | |
BR112014003556A2 (pt) | método de tratamento de vírus, e, composição farmacêutica | |
EP2719704A4 (en) | PROCESS FOR PRODUCING INJECTABLE FORMULATIONS FROM BLOOD-DERIVED PROTEIN MATERIAL AND MATERIALS PRODUCED BY THIS METHOD | |
BR112014013807A2 (pt) | composição de condicionamento de tecidos e processo para o tratamento de tecido | |
GB2502761B (en) | Method and internal control composition for determining the efficacy of enzymatic cell lysis | |
BR112014001439A2 (pt) | extrato proteolítico de bromelaína para o tratamento de distúrbios de tecido conjuntivo | |
IT1402643B1 (it) | Corpo per pedale strumentato e procedimento di produzione dello stesso. | |
WO2010070141A3 (en) | Microparticles comprising adipose stem cells | |
WO2013052736A9 (en) | Methods of treating or preventing blood loss during surgery using the serine protease inhibitor mdco-2010 | |
LU91877B1 (en) | Method to predict the presence of itaconic Acid, IRG1 and/or protein IRG1 in a subject and pharmaceutical composition for performing gene therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B25C | Requirement related to requested transfer of rights |
Owner name: BAXTER INTERNATIONAL INC. (US) , BAXTER HEALTHCARE |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: BAXALTA INCORPORATED (US) , BAXALTA GMBH (CH) |
|
B15G | Petition not considered as such [chapter 15.7 patent gazette] | ||
B15G | Petition not considered as such [chapter 15.7 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) |
|
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |